deferasirox:
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Transfusional Hemosiderosis
Conditions
Transfusional Hemosiderosis
Trial Timeline
May 1, 2009 → Aug 1, 2010
NCT ID
NCT00845871About deferasirox:
deferasirox: is a approved stage product being developed by Novartis for Transfusional Hemosiderosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00845871. Target conditions include Transfusional Hemosiderosis.
What happened to similar drugs?
0 of 1 similar drugs in Transfusional Hemosiderosis were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00845871 | Approved | Completed |
Competing Products
6 competing products in Transfusional Hemosiderosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Deferasirox | Novartis | Phase 2 | 35 |
| ICL670 | Novartis | Phase 2 | 35 |
| deferasirox | Novartis | Pre-clinical | 26 |
| Deferasirox | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Phase 3 | 40 |
| Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + Deferoxamine | Novartis | Phase 2 | 35 |